For more than 60 years, influenza vaccines have been produced using the same basic technology and have provided safe and effective protection for millions of individuals. But changes may be on the horizon as scientists probe faster methods of producing the vaccines and strategies for boosting their efficacy, according to infectious disease experts, who gathered in Arlington, Va, in January for the Infectious Diseases Society of America's Seasonal and Pandemic Influenza meeting.
Graphic Jump Location
Using cell-based methods to produce an influenza vaccine is under investigation as a means to speed vaccine production, which currently takes several months.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
Table 11.1-5 Influence of Age on Effect Size Estimates of Trials Evaluating the Efficacy of Vaccination in Preventing Influenza in Healthy Adults
The Rational Clinical Examination
Ten percent to 20% of US residents contract influenza annually, accounting for an average of...
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.